BioFocus Announces Agreement with ChanTest
News Feb 07, 2013
BioFocus and ChanTest have announced an agreement which will enable BioFocus to offer ChanTest’s extensive cell line library (> 200 products) and Channel Panel™ profiling services.
This expands BioFocus’ offering in the fields of ion channel, GPCR and transporter targets for drug discovery.
“With access to ChanTest’s cell line collection and ion channel profiling, we have further augmented our suite of integrated drug discovery services, designed to deliver efficiency and success to our partners,” said Kate Hilyard, VP Biological Sciences, BioFocus.
Chris Mathes, Ph.D., M.B.A, Chief Commercial Officer, ChanTest, commented, “This collaboration with BioFocus fits well with ChanTest’s integrated CRO strategy, and we are delighted to partner with a company with such a strong reputation.”
A breakthrough has been made in the fight against Alzheimer's disease - researchers have found a new way to target the toxic particles that destroy healthy brain cells. Academics have devised the first strategy to 'go after' the cause of the devastating disease, leading to hope that new drugs could be developed to treat dementia.READ MORE